Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2025-02-28 Earnings Release
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad envía nota de prensa relativa a los resultados del ejercicio 2024 junto con informe financiero.
Earnings Release Classification · 100% confidence The document is titled "Nota de prensa" (Press Release) and explicitly states "El Grupo PharmaMar presenta resultados financieros del ejercicio 2024" (PharmaMar Group presents financial results for the 2024 fiscal year). It contains key financial highlights (revenues, EBITDA, net profit) for the full year 2024, dated February 28, 2025. It also includes a section titled "INFORME A 31 DE DICIEMBRE DE 2024" (REPORT AS OF DECEMBER 31, 2024) with detailed financial tables and operational milestones for the year. This structure—a press release summarizing annual financial performance—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results (in this case, annual results). While it contains comprehensive data, its format as a press release announcing the results, rather than the formal 10-K filing itself, points towards ER. It is not a full transcript (CT), a formal 10-K, or a quarterly report (IR), as it covers the full fiscal year. FY 2024
2025-02-28 Spanish
Annual Report 2024
Annual Report Classification · 100% confidence The document contains comprehensive financial statements for Pharma Mar, S.A. for the fiscal year ending December 31, 2024, including the Balance Sheet, Profit and Loss Account, Statement of Changes in Equity, and Cash Flow Statement. It is a full annual financial report rather than an announcement or a summary. Given the comprehensive nature of the financial data provided for the full fiscal year, it is classified as an Annual Report (10-K equivalent). FY 2024
2025-02-28 Spanish
Annual Report 2024
Annual Report Classification · 100% confidence The document is titled 'Cuentas anuales consolidadas e informe de gestión consolidado al 31 de diciembre de 2024' (Consolidated Annual Accounts and Management Report for the year ended December 31, 2024). It contains comprehensive financial statements including the Consolidated Balance Sheet, Income Statement, Statement of Comprehensive Income, Statement of Changes in Equity, Cash Flow Statement, and detailed explanatory notes (Memoria). This constitutes a full annual report for the fiscal year 2024, which aligns with the definition of a 10-K (Annual Report). FY 2024
2025-02-28 Spanish
Annual Report 2024
Annual Report Classification · 100% confidence The document is titled 'Cuentas anuales consolidadas e informe de gestión consolidado al 31 de diciembre de 2024' which translates to 'Consolidated annual accounts and management report as of December 31, 2024'. It contains detailed consolidated financial statements including balance sheet, income statement, statement of changes in equity, cash flow statement, and notes to the consolidated annual accounts. The document covers the full fiscal year ending December 31, 2024, and includes comprehensive financial data and management discussion. This matches the definition of an Annual Report (10-K) which is an official yearly report covering company activity and full financial performance. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-02-28 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre los días 17 y 21 de febrero de 2025. Finalización del Programa de
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish securities market regulator) dated February 24, 2025. The subject is the 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). It details transactions conducted under a previously announced Share Repurchase Program during the period February 17 to February 21, 2025, and explicitly states the completion of the program. This type of filing, detailing the company's own transactions in its shares (buybacks), directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K).
2025-02-24 Spanish
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa de Recompra de Acciones en el periodo transcurrido entre el 10 de febrero y el 14 de febrero de 2025.
Transaction in Own Shares Classification · 100% confidence The document is a formal communication to the 'Comisión Nacional del Mercado de Valores' (Spanish Securities Market Commission) dated February 17, 2025. The title is 'COMUNICACIÓN DE OTRA INFORMACIÓN RELEVANTE' (Communication of Other Relevant Information) and the subject is 'Programas de recompra de acciones, estabilización y autocartera' (Share repurchase programs, stabilization, and treasury stock). The content details specific 'Compra' (Buy) operations of the company's own shares (autocartera) executed between February 10 and February 14, 2025, including transaction dates, volume, and price. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2025-02-17 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.